Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study
- PMID: 31409413
- PMCID: PMC6693266
- DOI: 10.1186/s12913-019-4414-5
Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study
Abstract
Background: Bronchiectasis in children is an important, but under-researched, chronic pulmonary disorder that has negative impacts on health-related quality of life. Despite this, it does not receive the same attention as other chronic pulmonary conditions in children such as cystic fibrosis. We measured health resource use and health-related quality of life over a 12-month period in children with bronchiectasis.
Methods: We undertook a prospective cohort study of 85 children aged < 18-years with high-resolution chest computed-tomography confirmed bronchiectasis undergoing management in three pediatric respiratory medical clinics in Darwin and Brisbane, Australia and Auckland, New Zealand. Children with cystic fibrosis or receiving cancer treatment were excluded. Data collected included the frequency of healthcare attendances (general practice, specialists, hospital and/or emergency departments, and other), medication use, work and school/childcare absences for parents/carers and children respectively, and both parent/carer and child reported quality of life and cough severity.
Results: Overall, 951 child-months of observation were completed for 85 children (median age 8.7-years, interquartile range 5.4-11.3). The mean (standard deviation) number of exacerbations was 3.3 (2.2) per child-year. Thirty of 264 (11.4%) exacerbation episodes required hospitalization. Healthcare attendance and antibiotic use rates were high (30 and 50 per 100 child-months of observation respectively). A carer took leave from work for 53/236 (22.5%) routine clinic visits. Absences from school/childcare due to bronchiectasis were 24.9 children per 100 child-months. Quality of life scores for both the parent/carer and child were highly-correlated with one another, remained stable over time and were negatively associated with cough severity.
Conclusions: Health resource use in this cohort of children is high, reflecting their severe disease burden. Studies are now needed to quantify the direct and societal costs of disease and to evaluate interventions that may reduce disease burden, particularly hospitalizations.
Keywords: Bronchiectasis; Children; Health resource use; Health-related quality of life.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Cost of hospitalization for bronchiectasis exacerbation in children.Respirology. 2020 Dec;25(12):1250-1256. doi: 10.1111/resp.13828. Epub 2020 May 1. Respirology. 2020. PMID: 32358912
-
Is out-patient based treatment of bronchiectasis exacerbations in children comparable to inpatient based treatment?Pediatr Pulmonol. 2020 Apr;55(4):994-999. doi: 10.1002/ppul.24670. Epub 2020 Feb 18. Pediatr Pulmonol. 2020. PMID: 32068973
-
KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea.BMJ Open. 2020 Jan 19;10(1):e034090. doi: 10.1136/bmjopen-2019-034090. BMJ Open. 2020. PMID: 31959610 Free PMC article.
-
Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.Expert Rev Respir Med. 2018 Sep;12(9):769-782. doi: 10.1080/17476348.2018.1503540. Epub 2018 Aug 3. Expert Rev Respir Med. 2018. PMID: 30025482 Review.
-
Paediatric and adult bronchiectasis: Monitoring, cross-infection, role of multidisciplinary teams and self-management plans.Respirology. 2019 Feb;24(2):115-126. doi: 10.1111/resp.13451. Epub 2018 Nov 30. Respirology. 2019. PMID: 30500093 Review.
Cited by
-
Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial.BMJ Open Respir Res. 2022 May;9(1):e001236. doi: 10.1136/bmjresp-2022-001236. BMJ Open Respir Res. 2022. PMID: 35534039 Free PMC article.
-
Bronchiectasis in African children: Challenges and barriers to care.Front Pediatr. 2022 Jul 25;10:954608. doi: 10.3389/fped.2022.954608. eCollection 2022. Front Pediatr. 2022. PMID: 35958169 Free PMC article. Review.
-
Mucolytics for children with chronic suppurative lung disease.Cochrane Database Syst Rev. 2025 Mar 28;3(3):CD015313. doi: 10.1002/14651858.CD015313.pub2. Cochrane Database Syst Rev. 2025. PMID: 40152354
-
Gastrointestinal factors associated with risk of bronchiectasis in children.Pediatr Pulmonol. 2023 Mar;58(3):899-907. doi: 10.1002/ppul.26276. Epub 2022 Dec 20. Pediatr Pulmonol. 2023. PMID: 36510759 Free PMC article.
-
Burden of Care for Children with Bronchiectasis from Parents/Carers Perspective.J Clin Med. 2021 Dec 14;10(24):5856. doi: 10.3390/jcm10245856. J Clin Med. 2021. PMID: 34945152 Free PMC article.
References
-
- Schmets G, Rajan D, Kadandale S. Strategizing national health in the 21st century: a handbook. Geneva: WHO; 2016.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical